Sevelamer hydrochloride: An effective phosphate binder in dialyzed children

Pediatric Nephrology

Volumn 18, Issue 12, 2003, Pages 1260-1264

  Mahdavi, Homa ^a   Kuizon, Beatriz D ^a   Gales, Barbara ^a   Wang, He Jing ^a   Elashoff, Robert M ^a   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dialysis; End stage renal disease; Hyperphosphatemia; Phosphate binders

Indexed keywords

BICARBONATE; CALCITRIOL; CALCIUM; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; TRIACYLGLYCEROL; VITAMIN D DERIVATIVE;

ADOLESCENT; ADULT; ARTERY CALCIFICATION; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MALE; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; EPOXY COMPOUNDS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS; PILOT PROJECTS; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 0346270547     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-003-1298-7     Document Type: Article

References (30)

1. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M (1996) Direct effect of phosphorus on parathyroid hormone secretion from whole parathyroid glands in vitro. J Bone Miner Res 11:970-976
2. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ (1996) Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540
3. Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931-936
4. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM (1998) Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18:535-541
5. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC (1996) Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. Am J Kidney Dis 27:394-401
6. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S (1999) Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int [Suppl 71]:S238-S241
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483
8. Goodman WG (2001) Vascular calcification in chronic renal failure. Lancet 358:1115-1116
9. Coburn JW, Norris KC, Nebeker HG (1986) Osteomalacia and bone disease arising from aluminum. Semin Nephrol 6:68-89
10. Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN (1986) Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 108:767-770
11. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus M, Delmez J (1986) Calcium carbonate is an effective phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161
12. Andreoli SP, Dunson JW, Bergstein JM (1987) Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 9:206-210
13. Salusky IB, Goodman WG (2001) Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978-1985
14. Chertow GM, Burke SK, Lazarus JM, Stenzel K, Wombolt D, Goldberg DI, Bonventre JV, Slatopolsky E (1997) Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71
15. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK (1998) Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 13:2303-2310
16. Wilkes BM, Reiner D, Kern M, Burke S (1998) Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 50:381-386
17. Slatopolsky EA, Burke SK, Dillon MA (1999) RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 55:299-307
18. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky EA (1999) A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26
19. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252
20. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H (1999) A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287-4290
21. Gao P, Scheibel S, D'Amour P, John MR, Rao DS, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605-614
22. Chertow GM, Burke SK, Dillon MA, Slatopolsky E (1999) Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14:2709-2714
23. Salusky IB, Foley J, Nelson P, Goodman WG (1991) Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527-531
24. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617
25. Guerin AP, London GM, Marchais SJ, Metivier F (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021
26. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938-942
27. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH (1994) Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861
28. Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DSC, Eccestone A, Uldall PR (1998) Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 9:859-868
29. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A (1998) Control of serum phosphorus without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404
30. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100-105